MBX Biosciences, Inc. - Common Stock (MBX)
34.80
+4.38 (14.40%)
NASDAQ · Last Trade: Dec 22nd, 4:45 PM EST
Detailed Quote
| Previous Close | 30.42 |
|---|---|
| Open | 30.93 |
| Bid | 30.42 |
| Ask | 35.50 |
| Day's Range | 30.52 - 35.55 |
| 52 Week Range | 4.807 - 34.83 |
| Volume | 985,138 |
| Market Cap | - |
| PE Ratio (TTM) | 4.531 |
| EPS (TTM) | 7.7 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 948,648 |
Chart
About MBX Biosciences, Inc. - Common Stock (MBX)
MBX Biosciences, Inc. is a biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. The company leverages advanced science and technology to create novel drug candidates that aim to address unmet medical needs in these therapeutic areas. Through rigorous research and clinical trials, MBX aims to bring accessible and effective treatment options to patients suffering from conditions such as obesity, diabetes, and other hormone-related diseases, positioning itself as a key player in the biotechnology landscape. Read More
News & Press Releases
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts by surprise. After years of trading in the shadow of high interest rates and regulatory uncertainty, the industry
Via MarketMinute · December 22, 2025
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Via The Motley Fool · December 3, 2025
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Via The Motley Fool · November 27, 2025
MBX Stock Soars Pre-Market After Investigational Hypoparathyroidism Drug Yields Positive Results In Studystocktwits.com
Via Stocktwits · September 22, 2025
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results that are validating extensive research and development efforts across the industry. Investors are demonstrating a renewed appetite for risk,
Via MarketMinute · November 7, 2025
Via Benzinga · November 4, 2025
Let's have a look at the stocks with an unusual volume in today's session.
Via Chartmill · September 25, 2025
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc. (NASDAQ: SFIX) dipped 7.6% to $5.21 in pre-market trading following the release of fourth-quarter results.
Via Benzinga · September 25, 2025
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.
Via Benzinga · September 25, 2025
On Tuesday, there are stocks with unusual volume. Let's take a look.
Via Chartmill · September 23, 2025
U.S. stock futures were fluctuating on Tuesday following Monday's record advances. Futures of major benchmark indices were mixed.
Via Benzinga · September 23, 2025
U.S. stock futures down, focus on AutoZone, Firefly Aerospace earnings, AAR Corp. results, MBX Biosciences public offering.
Via Benzinga · September 23, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · September 22, 2025
Via Benzinga · September 22, 2025
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · September 22, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · September 22, 2025
Via Benzinga · September 22, 2025
Via Benzinga · September 22, 2025
The company is working on an experimental treatment for a thyroid disease.
Via Investor's Business Daily · September 22, 2025
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · September 22, 2025
MBX Biosciences reported Phase 2 trial success for once-weekly canvuparatide, with strong efficacy, safety profile, and plans for Phase 3 in 2026.
Via Benzinga · September 22, 2025
Via Benzinga · September 22, 2025
Via Benzinga · September 22, 2025
Via Benzinga · September 19, 2025